Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Henao-Restrepo AM"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    An introduction to the Marburg virus vaccine consortium, MARVAC.
    Autorzy:
    Cross RW; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Longini IM; Department of Biostatistics, University of Florida, Gainesville, Florida, United States of America.
    Becker S; Institute for Virology, Philipps-Universität Marburg, Marburg, Germany.
    Bok K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
    Boucher D; U.S. COVID-19 Response at U.S. Department of Health and Human Services, Washington, DC, United States of America.
    Carroll MW; Pandemic Sciences Institute, Nuffield Department of Medicine, Oxford University, United Kingdom.
    Díaz JV; World Health Organization, Geneva, Switzerland.
    Dowling WE; Coalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America.
    Draghia-Akli R; Johnson & Johnson-Global Public Health Research and Development, Spring House, Pennsylvania, United States of America.
    Duworko JT; Partnership for Research on Infectious Diseases in Liberia, Monrovia, Liberia.
    Dye JM; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, United States of America.
    Egan MA; Auro Vaccines, Pearl River, New York, United States of America.
    Fast P; IAVI, New York, New York, United States of America.
    Finan A; Sabin vaccine Institute, Washington, DC, United States of America.
    Finch C; Sabin vaccine Institute, Washington, DC, United States of America.
    Fleming TR; University of Washington, Seattle, Washington, United States of America.
    Fusco J; Public Health Vaccines, Cambridge, Massachusetts, United States of America.
    Geisbert TW; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Griffiths A; National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America.
    Günther S; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
    Hensley LE; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America.
    Honko A; National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America.
    Hunegnaw R; Immune Biology of Retroviral Infection Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
    Jakubik J; Sabin vaccine Institute, Washington, DC, United States of America.
    Ledgerwood J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
    Luhn K; Janssen Vaccines & Prevention, Leiden, the Netherlands.
    Matassov D; Auro Vaccines, Pearl River, New York, United States of America.
    Meshulam J; Auro Vaccines, Pearl River, New York, United States of America.
    Nelson EV; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
    Parks CL; IAVI, New York, New York, United States of America.
    Rustomjee R; Sabin vaccine Institute, Washington, DC, United States of America.
    Safronetz D; Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
    Schwartz LM; World Health Organization, Geneva, Switzerland.
    Smith D; Bacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada.
    Smock P; Sabin vaccine Institute, Washington, DC, United States of America.
    Sow Y; Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
    Spiropoulou CF; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
    Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
    Warfield KL; Emergent BioSolutions, Gaithersburg, Maryland, United States of America.
    Wolfe D; Bacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada.
    Woolsey C; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Zahn R; Janssen Vaccines & Prevention, Leiden, the Netherlands.
    Henao-Restrepo AM; World Health Organization, Geneva, Switzerland.
    Muñoz-Fontela C; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
    Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2022 Oct 13; Vol. 18 (10), pp. e1010805. Date of Electronic Publication: 2022 Oct 13 (Print Publication: 2022).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Marburg Virus Disease*/prevention & control
    Marburgvirus*
    Viral Vaccines*
    Animals ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Advances and gaps in SARS-CoV-2 infection models.
    Autorzy:
    Muñoz-Fontela C; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
    Widerspick L; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
    Albrecht RA; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
    Beer M; Friedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald-Insel Riems, Germany.
    Carroll MW; National Infection Service, Public Health England, Salisbury, United Kingdom.; Pandemic Sciences Centre, Nuffield Department of Medicine, Oxford University, United Kingdom.
    de Wit E; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
    Diamond MS; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
    Dowling WE; Coalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America.
    Funnell SGP; National Infection Service, Public Health England, Salisbury, United Kingdom.
    García-Sastre A; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
    Gerhards NM; Wageningen Bioveterinary Research, Lelystad, the Netherlands.
    de Jong R; Wageningen Bioveterinary Research, Lelystad, the Netherlands.
    Munster VJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
    Neyts J; KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
    Perlman S; Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.
    Reed DS; Center for Vaccine Research and Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
    Richt JA; Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, United States of America.
    Riveros-Balta X; World Health Organization, Geneva, Switzerland.
    Roy CJ; Tulane National Primate Research Center, Covington, Louisiana, United States of America.
    Salguero FJ; National Infection Service, Public Health England, Salisbury, United Kingdom.
    Schotsaert M; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
    Schwartz LM; World Health Organization, Geneva, Switzerland.
    Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
    Segalés J; Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus UAB, and Departament de Sanitat i Anatomia animals, Facultat de Veterinària, UAB, Barcelona, Spain.
    Vasan SS; Australian Centre for Disease Preparedness, CSIRO, Geelong, Australia.
    Henao-Restrepo AM; World Health Organization, Geneva, Switzerland.
    Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2022 Jan 13; Vol. 18 (1), pp. e1010161. Date of Electronic Publication: 2022 Jan 13 (Print Publication: 2022).
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Disease Models, Animal*
    SARS-CoV-2*/immunology
    SARS-CoV-2*/pathogenicity
    COVID-19/*etiology
    Age Factors ; Animals ; COVID-19/prevention & control ; COVID-19/therapy ; COVID-19 Vaccines/adverse effects ; COVID-19 Vaccines/immunology ; Comorbidity ; Humans
    SCR Organism:
    SARS-CoV-2 variants
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Autorzy:
    Soto A; Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú.; Departamento de Medicina, Hospital Nacional Hipólito Unanue, Lima, Perú.
    Quiñones-Laveriano DM; Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú.
    Garcia PJ; Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Perú.
    Gotuzzo E; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú.
    Henao-Restrepo AM; Organización Mundial de la Salud, Ginebra, Suiza.
    Pokaż więcej
    Transliterated Title:
    Respuestas rápidas a la pandemia de COVID-19 a través de la ciencia y la colaboración global: el ensayo clínico Solidaridad.
    Źródło:
    Revista peruana de medicina experimental y salud publica [Rev Peru Med Exp Salud Publica] 2020 Apr-Jun; Vol. 37 (2), pp. 356-360. Date of Electronic Publication: 2020 Aug 28.
    Typ publikacji:
    Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Antiviral Agents/*administration & dosage
    Coronavirus Infections/*drug therapy
    Pneumonia, Viral/*drug therapy
    COVID-19 ; Coronavirus Infections/physiopathology ; Drug Therapy, Combination ; Humans ; International Cooperation ; Pandemics ; Peru ; Pneumonia, Viral/physiopathology ; Severity of Illness Index ; Treatment Outcome ; COVID-19 Drug Treatment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Data sharing for novel coronavirus (COVID-19).
    Autorzy:
    Moorthy V; Science Division, World Health Organization, avenue Appia 20, 1211 Geneva 27, Switzerland.
    Henao Restrepo AM; Health Emergencies Preparedness and Response, World Health Organization, Geneva, Switzerland.
    Preziosi MP; Universal Health Coverage/Life Course, World Health Organization, Geneva, Switzerland.
    Swaminathan S; Science Division, World Health Organization, avenue Appia 20, 1211 Geneva 27, Switzerland.
    Pokaż więcej
    Źródło:
    Bulletin of the World Health Organization [Bull World Health Organ] 2020 Mar 01; Vol. 98 (3), pp. 150.
    Typ publikacji:
    Editorial
    MeSH Terms:
    Betacoronavirus*
    Information Dissemination*
    Coronavirus Infections/*epidemiology
    Pneumonia, Viral/*epidemiology
    Pneumonia, Viral/*virology
    COVID-19 ; Coronavirus Infections/virology ; Humans ; Pandemics ; SARS-CoV-2
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Case based measles surveillance in Pune: evidence to guide current and future measles control and elimination efforts in India.
    Autorzy:
    Bose AS; National Polio Surveillance Project, India Country Office, World Health Organization, New Delhi, India; Vaccine Delivery, Bill & Melinda Gates Foundation, New Delhi, India.
    Jafari H; National Polio Surveillance Project, India Country Office, World Health Organization, New Delhi, India; Polio Operations & Research, World Health Organization, Geneva, Switzerland.
    Sosler S; National Polio Surveillance Project, India Country Office, World Health Organization, New Delhi, India; GAVI, The Vaccine Alliance, Geneva, Switzerland.
    Narula AP; National Polio Surveillance Project, India Country Office, World Health Organization, New Delhi, India.
    Kulkarni VM; Department of Health and Family Welfare, Govt. of Maharashtra, Pune, Maharashtra, India.
    Ramamurty N; Immunization & Vaccine Development, South-East Asia Regional Office, World Health Organization, New Delhi, India.
    Oommen J; Immunization & Vaccine Development, South-East Asia Regional Office, World Health Organization, New Delhi, India.
    Jadi RS; National institute of Virology, Indian Council of Medical Research, Pune, Maharashtra, India.
    Banpel RV; National Polio Surveillance Project, India Country Office, World Health Organization, New Delhi, India.
    Henao-Restrepo AM; Immunization Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2014 Oct 07; Vol. 9 (10), pp. e108786. Date of Electronic Publication: 2014 Oct 07 (Print Publication: 2014).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Population Surveillance*
    Measles/*epidemiology
    Adolescent ; Age Factors ; Child ; Child, Preschool ; Disease Outbreaks ; Female ; Geography, Medical ; Humans ; Incidence ; India/epidemiology ; Infant ; Infant, Newborn ; Male ; Measles/prevention & control ; Measles Vaccine ; Mortality ; Seasons ; Sex Factors ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies